Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-18
2005-10-18
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S369000
Reexamination Certificate
active
06956040
ABSTRACT:
The present invention relates to certain substituted phenyl piperazinyl oxazolidinones, for example, to those having the structure of Formula Iwith the variables as defined within, and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such asBacterioidesspp. andClostridiaspp. species, and acid fast organisms such asMycobacterium tuberculosis, Mycobacterium aviumandMycobacteriumspp.
REFERENCES:
patent: 4801600 (1989-01-01), Wang et al.
patent: 4921869 (1990-05-01), Wang et al.
patent: 5254577 (1993-10-01), Carlson et al.
patent: 5547950 (1996-08-01), Hutchinson et al.
patent: 5700799 (1997-12-01), Hutchinson et al.
patent: 5981528 (1999-11-01), Gravestock
patent: 6277985 (2001-08-01), Gadwood et al.
patent: 0 352 781 (1989-07-01), None
patent: 0 312 000 (1992-03-01), None
patent: WO 90/02744 (1990-03-01), None
patent: WO 93/09103 (1993-05-01), None
patent: WO 93/23384 (1993-11-01), None
patent: WO 95/14684 (1995-06-01), None
patent: WO 95/25106 (1995-09-01), None
patent: WO 97/14690 (1997-04-01), None
patent: WO 98/01446 (1998-01-01), None
patent: WO 00/32599 (2000-06-01), None
patent: WO 02/06278 (2002-01-01), None
Foye, William O. et al, “Principles of Medicianl Chemistry, 4ed”, Williams & Wilkins, 1995, Baltimore, 83, 89 and 111-113.
Testa, B.,. “Burger's Medicinal Chemistry, 5ed, Part I, Wolff, Manfred Ed.”, John Wiley & Sons, 1995, pp. 129, 130, and 143-146.
Gregory W.A., et al., “Antibacterials. Synthesis and Structure—Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The “B” Group,” J.Med.Chem., 32, 1673-81 (1989).
Gregory W.A., et al., “Antibacterials. Synthesis and Structure—Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The “A” Group,” J.Med.Chem., 33, 2569-78 (1990).
Wang C., et al., “Chiral Synthesis of Dup 721, A New Antibacterial Agent”, Tetrahedron, 45, 1323-26 (1989).
Brittelli, et al., “Antibacterials. Synthesis and Structure—Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives,” J.Med. Chem., 35, 1156 (1992).
Pae, et al., “Synthesis and in Vitro Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles,” Bio-organic and Medicinal Chemistry Letters, 9, pp. 2679-2684, 1999.
Pae, et al., “3D QSAR Studies on New Oxazolidinone Antibacterial Agents by Comparitave Molecular Field Analysis,” Bioorganic & Medicinal Chemistry Letters 9, pp. 2685-2690, 1999.
Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, Jun. 28-29, 2001, Amsterdam, The Netherlands; Poster Nos. 1822-1834.
40thInterscience Conference on Antimicrobial Agents and Chemotherapy, Sep. 17-20, 2000, Toronto, Canada.
Blake and Metcalfe, “A Shared Noncapsular Antigen Is Responsible for False-Positive Reactions byStaphylococcus epidermisin Commercial Agglutination Tests forStaphylococcus aureus”, Journal of Clinical Microbiology, 39(2):544-550 (2001).
Borch et al., “Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkalyting Agents,”Journal of Medicinal Chemistry, 43: 2258-2265 (2000).
Fournari and Tirouflet,Bull. Soc. Chim. France,p 484-487 (1963).
Chemical Abstracts,71:332, abst. 101697d (1969).
Mermel et al., “Guidelines for the Management of Intravascular Catheter-Related Infections”,Clinical Infectious Diseases, 32:1249-1272 (2001).
Divald, et al, “Chemistry of 2-(Chloromethyl)furans. Reaction of 2-(Chloromethyl)futans with Aqueous Potassium Cyanide and Other Nucleophiles”,Journal of Organic Chemistry, 41:2835-2845 (1976).
Gilman et al, “Orientation in the Furan Nucleau:, VI. β- Substituted Furans”,Journal of the American Chem. Society, 55:2903-2909 (1933).
Hulbert, et al, “Structure and Antischistosomal Activity in the Nitrofuran Series. Requirement for a 5-Nitro-2-furyl Vinyl Moiety Based on Comparison of 3-5-Nitro-2-furyl-Substituted Propionic, Acrylic, and Propiolic Acid Derivatives.”,Journal of Medicinal Chemistry, 16:72-78 (1973).
Zimmerli, “Experimental models in the investigation of device-related infections”,Journal of Antimicrobial Chemotherapy 31(Suppl. D):97-102 (1993).
Khim.Geterosikl. Soedin., 6:747-50 (1982).
Makosza, et al, “Dihalomethylation of Nitroarenes via Vicarious Nucleophilic Substitution of Hydrogen with Trihalomethyl Carbanions.”,Journal of Organic Chemistry, 54:5094-5100 (1989).
Park et al, “Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazoidines. 4. Multiply-Substituted Aryl Derivatives”,Journal of Medicinal Chemistry, 35:1156-1165 (1992).
Polonio et al., “Eradication of Biofilm-FormingStaphylococcus epidermis(RP62A) by a Combination of Sodium Salicylate and Vancomycin”,Antimicrobial Agents and Chemotherapy, 45(11):3262-3266 (2001).
Tanaka, et al, “Studies on Furan Derivatives. IX.1)Nucleophilic Substitution of 5-Nitro-2-furancarbaldehyde: Preparation of 5-Phenoxy-2-furancarbaldehydes.”,Chemical&Pharmaceutical Bulletin, 28(9):2846-2849 (1980).
“Catheter-Related Bloodstream Infections—Developing Antimicrobial Drugs for Treatment”,FDA Guidance for Industry(Oct. 1999).
Arora Sudershan K.
Das Bis{umlaut over (w)}ajit
Mehta Anita
Rattan Ashok
Ray Abhijit
Deshmukh, Esq. Jay R.
Heibel, Esq. George F.
McKenzie Thomas C.
Ranbaxy Laboratories Limited
LandOfFree
Oxazolidinone piperazinyl derivatives as potential... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazolidinone piperazinyl derivatives as potential..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolidinone piperazinyl derivatives as potential... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467248